a study of the recurrence of hepatitis c virus after achieving a sustained virological response

Background: hepatitis c virus (hcv) infection continues to be a major public health concern. the advancement of direct-acting antivirals (daas) has transformed hcv therapy, making viral elimination possible. nonetheless, experiencing a relapse following treatment continues to be a difficulty. objectives: this research intended to evaluate the rate of hcv relapse 84 months after finishing daa treatment. methods: the study included 89 patients who had finished daa therapy and achieved a sustained virologic response (svr). these patients were monitored for as long as 84 months, with yearly follow-up appointments. serological assessments for hiv and hepatitis b surface antigen (hbsag) and hcv-rtpcr were performed. the average age of the participants was 23 years (± 7 years). results: among the 89 patients, 41 (46.07%) exhibited genotype 1 (g1), 7 (7.87%) displayed genotype 3 (g3), and 41 (46.07%) represented genotype 4 (g4). the group was made up of 52 males (58.43%) and 37 females (41.57%). a co-morbid condition, thalassemia, was observed in 10 (11.24%). no patients showed positive results for hiv or hepatitis b. during the 84-month follow-up, no relapses or reinfections were noted. conclusions: the research validates the effectiveness of daas in attaining a sustained virologic response and preventing hcv recurrence. additional research involving larger groups and extended follow-up times is necessary to confirm these results.